Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Revaprazan

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract The purpose of this research was to develop a novel revaprazan-loaded surface-modified solid dispersion (SMSD) with… Expand
Review
2016
Review
2016
Acid-related diseases (ARDs), such as peptic ulcers and gastroesophageal reflux disease, represent a major health-care concern… Expand
2015
2015
Background/Aims Proton pump inhibitors (PPIs) act by irreversibly binding to the H+-K+-ATPase of the proton pump in parietal… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2012
2012
Chronic gastric inflammation developing after Helicobacter pylori (H. pylori) infection is responsible for either dyspeptic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2012
2012
Background/Aims: Proton pump inhibitors (PPIs) are widely used to prevent nonsteroidal anti-inflammatory drug (NSAID)-induced… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2010
2010
Background and Aim:  Revaprazan is a novel acid pump antagonist. The aim of this study was to investigate the inhibitory effect… Expand
2009
2009
Inhibition of H+,K+-ATPase is accepted as the most effective way of controlling gastric acid secretion. However, current acid… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2007
2007
Background/Aims: This randomized, double-blind, phase III, multicenter trial was carried out to compare the efficacy and safety… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
2007
2007
The present invention provides a water-soluble polymer, a water-soluble saccharide, a surfactant, or a mixture thereof formulas… Expand
2005
2005
Background/Aims: To assess the comparative efficacy and safety of revaprazan, a novel acid pump antagonist, versus omeprazole in… Expand